Journal of Neuroimmune Pharmacology

, Volume 1, Issue 1, pp 65–76 | Cite as

Combined and Independent Effects of Chronic Marijuana Use and HIV on Brain Metabolites

Invited Review

Abstract

The effects of chronic marijuana (MJ) use on brain function remain controversial. Because MJ is often used by human immunodeficiency virus (HIV) patients, the aim of this study was to evaluate whether chronic MJ use and HIV infection are associated with interactive or additive effects on brain chemistry and cognitive function. We evaluated 96 subjects (30 seronegative nondrug users, 24 MJ users, 21 HIV without MJ use, 21 HIV + MJ) using proton magnetic resonance spectroscopy and a battery of neuropsychological tests. The two primarily abstinent MJ user groups showed no significant differences on calculated estimates of lifetime grams of delta9-tetrahydrocannabinol exposure, despite some differences in usage pattern. The two HIV groups also had similar HIV disease severity (CD4 cell count, plasma viral load, HIV dementia staging, Karnofsky score). On two-way analyses of covariance, HIV infection (independent of MJ) was associated with trends for reduced N-acetyl aspartate (NA) in the parietal white matter and increased choline compounds (CHO) in the basal ganglia. In contrast, MJ (independent of HIV) was associated with decreased basal ganglia NA (−5.5%, p = 0.05), CHO (−10.6%, p = 0.04), and glutamate (−9.5%, p = 0.05), with increased thalamic creatine (+6.1%, p = 0.05). HIV + MJ was associated with normalization of the reduced glutamate in frontal white matter (interaction p = 0.01). After correction for age, education, or mood differences, MJ users had no significant abnormalities on neuropsychological test performance, and HIV subjects only had slower reaction times. These findings suggest chronic MJ use may lead to decreased neuronal and glial metabolites, but may normalize the decreased glutamate in HIV patients.

Keywords

proton magnetic resonance spectroscopy neuropsychological tests HIV marijuana cognitive function 

References

  1. Adle-Biassette H, Chretien F, Wingertsmann L, Hery C, Ereau T, Scaravilli F, Tardieu M, Gray F (1999) Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol. Appl. Neurobiol. 25:123–133CrossRefPubMedGoogle Scholar
  2. Anonymous (1994) Army individual test battery: manual of directions and scoring. War Department, Adjutant General's Office, Washington, DCGoogle Scholar
  3. Blair J, Spreen O (1989) The new adult reading test—revised manual. University of Victoria, Victoria, CanadaGoogle Scholar
  4. Bolla K, Brown K, Eldreth D, Tate K, Cadet J (2002) Dose-related neurocognitive effects of marijuana use. Neurology 9:1337–1343Google Scholar
  5. Bolla K, Eldreth D, Matochik J, Cadet J (2005) Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage 26:480–492CrossRefPubMedGoogle Scholar
  6. Brand A, Richter-Landsberg C, Leibfritz D (1993) Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev. Neurosci. 15:289–298PubMedCrossRefGoogle Scholar
  7. Budka H, Costanzi G, Cristina S, Lechi A, Parravicini C, Trabattoni R, Vago L (1987) Brain pathology induced by infection with the human immunodeficiency virus (HIV). A histological, immunocytochemical and electron microscopical study of 100 autopsy cases. Acta Neuropathol 75:185–198CrossRefPubMedGoogle Scholar
  8. Cabral GA, Dove Pettit DA (1998) Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 83:116–123CrossRefPubMedGoogle Scholar
  9. Chang L, Ernst T, Poland R, Jenden D (1996) In vivo proton magnetic resonance spectroscopy of the normal human aging brain. Life Sci 58:2049–2056CrossRefPubMedGoogle Scholar
  10. Chang L, Ernst T, Strickland T, Mehringer CM (1999a) Gender effects on persistent cerebral metabolite changes in the frontal lobes of abstinent cocaine users. Am J Psychiatry 156:716–722PubMedGoogle Scholar
  11. Chang L, Ernst T, Grob CS, Poland RE (1999b) Cerebral 1H MRS abnormalities in 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) users. J Magn Reson Imaging 10:521–526CrossRefPubMedGoogle Scholar
  12. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E (1999c) Cerebral metabolite abnormalities correlate with clinical severity of HIV-cognitive motor complex. Neurology 52:100–108PubMedGoogle Scholar
  13. Chang L, Ernst T, Leonido-Yee M, Speck O (2000) Perfusion MRI detects rCBF abnormalities in early stages of HIV-cognitive motor complex. Neurology 54:389–396PubMedGoogle Scholar
  14. Chang L, Ernst T, Witt M, Ames N, Jocivich J, Speck O, Gaiefsky M, Walot I, Miller E (2002) Relationships among cerebral metabolites, cognitive function and viral loads in antiretroviral-naïve HIV patients. NeuroImage 17:1638–1648CrossRefPubMedGoogle Scholar
  15. Chang L, Tomasi D, Yakupov R, Lozar C, Arnold S, Caparelli E, Ernst T. Adaptation of the attention network in human immunodeficiency virus brain injury. Ann. Neurol. 56:259–272, 2004.CrossRefPubMedGoogle Scholar
  16. Charalambous A, Marciniak G, Shiue C, Dewey S, Schlyer D, Wolf A, Makriyannis A (1991) PET studies in the primate brain and biodistribution in mice using (−)-5′-18F-delta 8-THC. Pharmacol Biochem Behav 40:503–507CrossRefPubMedGoogle Scholar
  17. Copper J, Bloom F, Roth R (1996) The Biochemical Basis of Neuropharmacology seventh edition, Oxford University Press, Inc. New YorkGoogle Scholar
  18. Cristiani SA, Pukay-Martin ND, Bornstein RA (2004) Marijuana use and cognitive function in HIV-infected people. J Neuropsychiatry Clin Neurosci 16:330–335PubMedGoogle Scholar
  19. Eldreth D, Matochik J, Cadet J, Bolla K (2004) Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. NeuroImage 23:914–920CrossRefPubMedGoogle Scholar
  20. Ernst T, Kreis R, Ross BD (1993) Absolute quantitation of water and metabolites in the human brain. I. Compartments and water. J Magn Reson B102:1–8Google Scholar
  21. Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54:1344–1349PubMedGoogle Scholar
  22. Ernst T, Chang L, Arnold S (2003) Increased glial markers predict increased working memory network activation in HIV patients. NeuroImage 19:1686–1693CrossRefPubMedGoogle Scholar
  23. Ferrarese C, Aliprandi A, Tremolizzo L, Stanzani L, De Micheli A, Dolara A, Frattola L (2001) Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 57:671–675PubMedGoogle Scholar
  24. Goncharov I, Weiner L, Vogel Z (2005) Delta9-tetrahydrocannabinol increases C6 glioma cell death produced by oxidative stress. Neuroscience 134:567–574CrossRefPubMedGoogle Scholar
  25. Grant I, Atkinson J, Hesselink J (1987) Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other immunodeficiency virus (HIV) infections. Ann Intern Med 107:828–836PubMedGoogle Scholar
  26. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T (2003) Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 9:679–689CrossRefPubMedGoogle Scholar
  27. Gruber SA, Yurgelun-Todd DA (2005) Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain Res Cogn Brain Res 23:107–118CrossRefPubMedGoogle Scholar
  28. Heaton R, Grant I, Butters N, White D, Kirson D, Atkinson J, McCutchan J, Taylor M, Kelly M, Ellis R (1995) The HNRC 500—neuropsychology of HIV infection at different stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1:231–251PubMedGoogle Scholar
  29. Ke Y, Streeter C, Nassar L, Sarid-Segal O, Hennen J, Yurgelun-Todd D, Awad L, Rendall M, Gruber S, Nason A, Mudrick M, Blank S, Meyer A, Knapp C, Ciraulo D, Renshaw P (2004) Frontal lobe GABA levels in cocaine dependence: a two-dimensional, J-resolved magnetic resonance spectroscopy study. Psychiatry Res 130:283–293PubMedCrossRefGoogle Scholar
  30. Klein TW, Friedman H, Specter S (1998) Marijuana, immunity and infection. J Neuroimmunol 83:102–115CrossRefPubMedGoogle Scholar
  31. Klein TW, Lane B, Newton CA, Friedman H (2000) The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225:1–8CrossRefPubMedGoogle Scholar
  32. Kløve H (1963) Clinical neuropsychology. In: Forster F (ed) The Medical Clinics of North America, WB Saunders, New York, pp 110–125Google Scholar
  33. Kreis R, Ernst T, Ross BD (1993) Absolute quantitation of water and metabolites in the human brain. II. Metabolite concentrations. J Magn Reson B102:9–19Google Scholar
  34. Lee JH, Garwood M, Menon R, Adriany G, Andersen P, Truwit CL, Ugurbil K (1995) High contrast and fast three-dimensional magnetic resonance imaging at high fields. Magn Reson Med 34:308–312PubMedCrossRefGoogle Scholar
  35. Maccarrone M, Finazzi-Agro A (2003) The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ 10:946–955CrossRefPubMedGoogle Scholar
  36. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80:448–456CrossRefPubMedGoogle Scholar
  37. Martin E, Pitrak D, Pursell K, Mullane K, Novak R (1995) Delayed recognition memory span in HIV-1 infection. J Int Neuropsychol Soc 1:575–580PubMedCrossRefGoogle Scholar
  38. Miller EN (1990) California Computerized Assessment Package. In Custom Edition, Norland Software, Los AngelesGoogle Scholar
  39. Miller EN, Selnes OA, McArthur JC, Satz P, Becker JT, Cohen BA, Sheridan K, Machado AM, Van Gorp WG, Visscher B (1990) Neuropsychological performance in HIV-1 infected homosexual men: the Multicenter AIDS Cohort Study (MACS). Neurology 40:197–203PubMedGoogle Scholar
  40. O'Leary D, Block R, Koeppel J, Flaum M, Schultz S, Andreasen N, Ponto L, Watkins G, Hurtig R, Hichwa R (2002) Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26:802–816CrossRefPubMedGoogle Scholar
  41. Patel N, Moldow R, Patel J, Wu G, Chang S (1998) Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain. Brain Res 797:225–233CrossRefPubMedGoogle Scholar
  42. Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL, Devoto P (2002) Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948:155–158CrossRefPubMedGoogle Scholar
  43. Pope HJ, Yurgelun-Todd D (1996) The residual cognitive effects of heavy marijuana use in college students. J Am Med Assoc 275:521–527CrossRefGoogle Scholar
  44. Pope HJ, Gruber A, Hudson J, Huestis M, Yurgelun-Todd D (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58:909–915CrossRefPubMedGoogle Scholar
  45. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P (1988) The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 239:586–592PubMedCrossRefGoogle Scholar
  46. Provencher S (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672PubMedCrossRefGoogle Scholar
  47. Radloff LL (1997) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRefGoogle Scholar
  48. Rey A (1941) L'examen psycholoqiue dans les cas d'encephalopathie traumatique. Arch Psychol 28:286–340Google Scholar
  49. Rottenberg DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, Nelson MJ, Price RW (1996)Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 37:1133–1141PubMedGoogle Scholar
  50. Shen M, Thayer SA (1999) Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55:8–13PubMedGoogle Scholar
  51. Smith A (1982) Symbol Digit Modalities Test: Western Psychological ServicesGoogle Scholar
  52. Soher B, Hurd R, Sailasuta N, Barker P (1996) Quantitation of automated single-voxel proton MRS using cerebral water as an internal reference. Magn Reson Med 36:335–339PubMedCrossRefGoogle Scholar
  53. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. J Am Med Assoc 287:1123–1131CrossRefGoogle Scholar
  54. Stroop J (1935) Studies of interference in serial verbal reaction. J Exp Psychol 18:643–662CrossRefGoogle Scholar
  55. Tomasini MC, Ferraro L, Bebe BW, Tanganelli S, Cassano T, Cuomo V, Antonelli T (2002) Delta(9)-tetrahydrocannabinol increases endogenous extracellular glutamate levels in primary cultures of rat cerebral cortex neurons: involvement of CB(1) receptors. J Neurosci Res 68:449–453CrossRefPubMedGoogle Scholar
  56. Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, Lorenzini P, Visco-Comandini U, Vlassi C, Quartuccio M, Giulianelli M, Noto P, Galgani S, Ippolito G, Antinori A, Narciso P (2005) Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retrovir 21:706–713CrossRefPubMedGoogle Scholar
  57. Volkow N, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A, Hollister L (1996) Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res 67:29–38PubMedCrossRefGoogle Scholar
  58. Watson SJ, Benson JA Jr, Joy JE (2000) Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry 57:547–552CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Department of Medicine, John A. Burns School of MedicineQueen's University TowerHonoluluUSA

Personalised recommendations